Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALNY source : Www.globenewswire.com save search
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
TSVT | $4.52 -2.59% -2.65% 610K
|
|
| O: -1.16%
H: 9.94%
C: 2.34%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.23%
H: 1.0%
C: 0.17%
year financial results
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
Published: 2023-11-03 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.79%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -3.04%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 2.37%
H: 0.12%
C: -2.54%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 1.95%
H: 2.7%
C: 1.62%
disorders pipeline blood
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.08%
H: 4.96%
C: 3.4%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: 2.35%
H: 1.63%
C: 1.46%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
financial results
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.9%
H: 2.27%
C: 0.68%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.16%
H: 1.43%
C: 0.43%
meeting hepatitis liver presentation
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 7.75%
H: 4.65%
C: -3.9%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.36%
H: 2.51%
C: -2.16%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -1.97%
update financial results
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Published: 2023-08-03 (Crawled : 11:00) - globenewswire.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: -2.4%
H: 5.98%
C: 2.81%
license treatment potential agreement
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
Published: 2023-06-24 (Crawled : 12:20) - globenewswire.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
| Email alert
Add to watchlist
VIR | $7.96 0.0% 1.1M
|
Health Technology
| Email alert
Add to watchlist
vir-2218 hepatitis vir-3434 potential
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
Published: 2023-06-07 (Crawled : 06:00) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.38%
H: 1.85%
C: -0.15%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.46%
H: 0.17%
C: -0.99%
hepatitis presentation
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
Published: 2023-05-11 (Crawled : 12:20) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.74%
H: 0.52%
C: -0.04%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -2.4%
vir-2218 hepatitis virus trial
Regeneron Reports First Quarter 2023 Financial and Operating Results
Published: 2023-05-04 (Crawled : 10:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -3.44%
H: 0.13%
C: -2.79%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 1.11%
H: 2.3%
C: 1.82%
financial results
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.18%
H: 0.23%
C: -2.9%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -6.24%
H: 0.08%
C: -4.98%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.28%
H: 4.07%
C: -1.04%
year financial update results
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.09%
H: 0.59%
C: -0.21%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
treatment fda disease children review
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
Published: 2022-11-06 (Crawled : 16:20) - globenewswire.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
| Email alert
Add to watchlist
VIR | $7.96 0.0% 1.1M
|
Health Technology
| Email alert
Add to watchlist
vir-2218 hepatitis virus potential infection chronic hepatitis b
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
Published: 2022-10-24 (Crawled : 20:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.12%
H: 2.54%
C: 1.26%
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-11 (Crawled : 22:00) - globenewswire.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.0%
H: 3.23%
C: 1.94%
update results
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Published: 2022-08-11 (Crawled : 14:20) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.42%
H: 0.6%
C: -0.28%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.5%
C: -0.5%
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 0.85%
H: 5.47%
C: 2.45%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: -1.2%
H: 2.6%
C: -3.36%
BEAM | $23.9 -1.69% -1.72% 4.5M
|
Health Technology
|
| O: 1.31%
H: 10.03%
C: -0.75%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.04%
H: 1.13%
C: -1.08%
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: 0.28%
H: 0.71%
C: -8.16%
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Published: 2022-06-25 (Crawled : 12:20) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
VIR | $7.96 0.0% 1.1M
|
Health Technology
| Email alert
Add to watchlist
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
| Email alert
Add to watchlist
hepatitis program
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 12:00) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 5.76%
H: 0.45%
C: -5.37%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 4.17%
H: 0.0%
C: 0.0%
hepatitis liver presentation international
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
Published: 2022-04-27 (Crawled : 13:00) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -3.68%
H: 1.77%
C: -2.91%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.4%
H: 1.24%
C: -0.53%
day hepatitis program
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
hepatitis potential biotech technology iot liver injection infections chronic hepatitis b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.